Telomerase inhibitors TMPyP4 and BIBR 1532 show synergistic antitumor activity in combination with chemotherapeutic drugs.

ABSTRACT: We investigated the in vitro pharmacodynamic interactions of telomerase inhibitors (TMPyP4 and BIBR1532) with three anticancer drugs (cisplatin, doxorubicin, and paclitaxel) on a broad range of human cancer cell lines (MCF-7, MDA-MB-231, HeLa, U-118 MG, OVCAR-3, MCF-12A), selected based on the basal level of hTERT. The drug combination approach was performed using a combination index (CI), the Chou-Talalay method. The HeLa cells show the highest level of hTERT among the studied cell lines, and the second level was noted in the MCF-7 cells. Almost all used combinations in this line revealed a synergistic effect, with the lowest CI for BIBR1532 and cisplatin. Interestingly, the highest synergistic effect, compared to other combinations, was shown by BIBR1532 and doxorubicin in U118 MG cells.

SUBMITTER: Romaniuk-Drapala A 

PROVIDER: S-EPMC12475129 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature